Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237411 | 1.00 | CHRM2 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22324118 | 0.85 | CHRM2 (0.40) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL16237040 | 0.85 | CHRM2 (0.40) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL28650837 | 0.82 | NR1H2 (0.41) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL16240502 | 0.82 | NR1H2 (0.41) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL16237449 | 0.79 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22323878 | 0.79 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7688348 | 0.78 | CHRM2 (0.36) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL7683672 | 0.78 | THRB (0.41) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 | |
| SCHEMBL16249858 | 0.77 | THRB (0.38) | CHRM2CHRM4CHRM5KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3920928-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113661162-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020163544-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | CHRM2 4724/4885CHRM4 4560/4885CHRM5 4651/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CHRM2 4693/4885CHRM4 4535/4885CHRM5 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.